Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Biosimilars-Curb Your Enthusiasm.

Literature DB >> 28594963

Biosimilars-Curb Your Enthusiasm.

Y Tony Yang¹, Brian Chen², Charles L Bennett³.

Abstract

Mesh：

Substances：

Year: 2017 PMID： 28594963 DOI： 10.1001/jamaoncol.2017.1530

Source DB: PubMed Journal: JAMA Oncol ISSN： 2374-2437 Impact factor: 31.777

Keyword Cloud
Cited

× No keyword cloud information.

6 in total

1. Regulatory and Clinical Experiences with Biosimilar Filgrastim in the U.S., the European Union, Japan, and Canada.

Authors: Brian Chen; Sumimasa Nagai; James O Armitage; Bartlett Witherspoon; Chadi Nabhan; Ashley C Godwin; Y Tony Yang; Anuhya Kommalapati; Sri Harsha Tella; Carlo DeAngelis; Dennis W Raisch; Oliver Sartor; William J Hrushesky; Paul S Ray; Paul R Yarnold; Bryan L Love; LeAnn B Norris; Kevin Knopf; Laura Bobolts; Joshua Riente; Stefano Luminari; Robert C Kane; Shamia Hoque; Charles L Bennett
Journal: Oncologist Date: 2019-03-06

2. Why Biologics and Biosimilars Remain So Expensive: Despite Two Wins for Biosimilars, the Supreme Court's Recent Rulings do not Solve Fundamental Barriers to Competition.

Authors: Brian K Chen; Y Tony Yang; Charles L Bennett
Journal: Drugs Date: 2018-11 Impact factor: 9.546

Biosimilars-Curb Your Enthusiasm.

1. Regulatory and Clinical Experiences with Biosimilar Filgrastim in the U.S., the European Union, Japan, and Canada.

2. Why Biologics and Biosimilars Remain So Expensive: Despite Two Wins for Biosimilars, the Supreme Court's Recent Rulings do not Solve Fundamental Barriers to Competition.

Review 3. Are Biosimilars the Future of Oncology and Haematology?

4. Changes in Medicare Part B Spending for Biologic Drugs After Biosimilar Entry Into the Market.

Review 5. Biosimilars: Science, Implications, and Potential Outlooks in the Middle East and Africa.

6. Barriers to Oncology Biosimilars Uptake in the United States.